Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma.
[hodgkin lymphoma, classical]
Brentuximab
vedotin
(
BV
)
is
an
antibody-drug
conjugate
that
targets
CD
30
-
positive
malignancies
via
an
anti-
CD
30
monoclonal
antibody
linked
to
monomethyl
auristatin
E
,
a
microtubule-disrupting
agent
,
by
a
protease-cleavable
linker
.
BV
has
received
accelerated
approval
from
the
US
Food
and
Drug
Administration
for
the
treatment
of
classical
Hodgkin
lymphoma
that
has
relapsed
either
after
autologous
stem
cell
transplantation
(
ASCT
)
or
after
two
lines
of
combination
chemotherapy
in
patients
ineligible
for
ASCT
,
and
in
systemic
anaplastic
large
cell
lymphoma
after
failure
of
at
least
one
line
of
multiagent
chemotherapy
.
Phase
I
studies
in
CD
30
-
positive
lymphomas
have
determined
the
maximum
tolerated
dose
to
be
1
.
8
mg
/
kg
intravenously
every
21
days
.
In
relapsed
/
refractory
Hodgkin
lymphoma
,
a
pivotal
Phase
II
study
of
single
-
agent
BV
showed
an
overall
response
rate
of
75
%
,
with
34
%
complete
responses
and
a
median
remission
duration
of
20
months
for
complete
responders
.
BV
has
a
modest
toxicity
profile
,
with
peripheral
neuropathy
as
one
of
the
most
clinically
significant
side
effects
,
and
this
is
largely
reversible
.
Therefore
,
BV
is
the
treatment
of
choice
for
patients
with
relapsed
/
refractory
Hodgkin
lymphoma
after
ASCT
or
two
standard
regimens
.
Ongoing
trials
are
evaluating
the
role
of
BV
as
salvage
therapy
prior
to
ASCT
and
for
maintenance
after
ASCT
for
patients
with
relapsed
/
refractory
disease
.
